至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Molecular integration of the anti-tropomyosin compound ATM-3507 into the coiled coil overlap region of the cancer-associated Tpm3.1.

Sci Rep. 2019-08; 
JancoMiro,RynkiewiczMichael J,LiLiang,HookJeff,EiffeEleanor,GhoshAnita,BöckingTill,LehmanWilliam J,HardemanEdna C,GunningPet
Products/Services Used Details Operation
Codon Optimization The sequence was optimized for expression in E. coli using the IDT codon optimization tool (https://sg.idtdna.com/CodonOpt), synthesized (GenScript Biotech Corp., NJ, USA) and subcloned into pET-26b(+) vector using EcoRI/HindIII restriction sites. Get A Quote

摘要

Tropomyosins (Tpm) determine the functional capacity of actin filaments in an isoform-specific manner. The primary isoform in cancer cells is Tpm3.1 and compounds that target Tpm3.1 show promising results as anti-cancer agents both in vivo and in vitro. We have determined the molecular mechanism of interaction of the lead compound ATM-3507 with Tpm3.1-containing actin filaments. When present during co-polymerization of Tpm3.1 with actin, H-ATM-3507 is incorporated into the filaments and saturates at approximately one molecule per Tpm3.1 dimer and with an apparent binding affinity of approximately 2 µM. In contrast, H-ATM-3507 is poorly incorporated into preformed Tpm3.1/actin co-polymers. CD spectroscopy... More

关键词